The Kidney Disease: Improving Global Outcomes (KDIGO) 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD–MBD) is a selective update of the prior CKD–MBD guideline published in 2009. The guideline update and the original publication are intended to assist practitioners caring for adults with CKD and those receiving long-term dialysis.

Development of the guideline update followed an explicit process of evidence review and appraisal. The approach adopted by the Work Group and the evidence review team was based on systematic reviews of relevant trials, appraisal of the quality of the evidence, and rating of the strength of recommendations according to the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. Searches of the English-language literature were conducted through September 2015 and were supplemented with targeted searches through February 2017. Final modification of the guidelines was informed by a public review process involving numerous stakeholders, including patients, subject matter experts, and industry and national organizations.

The update process resulted in the revision of 15 recommendations. This synopsis focuses primarily on recommendations for diagnosis of and testing for CKD–MBD and treatment of CKD–MBD that emphasizes decreasing phosphate levels, maintaining calcium levels, and addressing elevated parathyroid hormone levels in adults with CKD stage G3a to G5 and those receiving dialysis. Key elements include basing treatment on trends in laboratory values rather than a single abnormal result and being cautious to avoid hypercalcemia when treating secondary hyperparathyroidism.

肾脏疾病：改善全球预后（KDIGO）2017年临床实践指南更新，用于诊断，评估，预防和治疗慢性肾脏病-矿物质和骨疾病（CKD-MBD），是先前CKD-MBD指南的选择性更新该指南于2009年出版。该指南的更新和原始出版物旨在帮助从业者照顾患有CKD的成年人以及接受长期透析的成年人。

指南更新的制定遵循了明确的证据审查和评估过程。工作组和证据审查小组采用的方法是基于对相关试验的系统审查，证据质量的评估以及根据GRADE（建议评估，制定和评估的等级）对建议强度的评估方法。截至2015年9月对英语文献进行了搜索，并于2017年2月进行了有针对性的搜索。对指南的最终修改是由包括患者，主题专家以及行业和国家组织在内的众多利益相关者进行的公开审查流程提供的。

更新过程导致对15项建议的修订。本大纲主要针对CKD-MBD的诊断和测试以及CKD-MBD的治疗建议，这些建议着重于降低CKD G3a至G5期成人和接受透析的成年人的磷酸盐水平，维持钙水平并解决甲状旁腺激素水平升高的问题。关键要素包括根据实验室值趋势而不是单个异常结果进行治疗，并且在治疗继发性甲状旁腺功能亢进症时要谨慎避免高钙血症。